Dynamic regulation of $T_{FH}$ selection during the germinal centre reaction

The germinal centre is a dynamic microenvironment in which B cells that express high-affinity antibody variants produced by somatic hypermutation are selected for clonal expansion by limiting the numbers of $T$ follicular helper cells\(^1,2\). Although much is known about the mechanisms that control the selection of B cells in the germinal centre, far less is understood about the clonal behaviour of the $T$ follicular helper cells that help to regulate this process. Here we report on the dynamic behaviour of $T$ follicular helper cell clones during the germinal centre reaction. We find that, similar to germinal centre B cells, $T$ follicular helper cells undergo antigen-dependent selection throughout the germinal centre reaction that results in differential proliferative expansion and contraction. Increasing the amount of antigen presented in the germinal centre leads to increased division of $T$ follicular helper cells.

Competition between $T$ follicular helper cell clones is mediated by the affinity of $T$ cell receptors for peptide-major-histocompatibility-complex ligands. $T$ cells that preferentially expand in the germinal centre show increased expression of genes downstream of the $T$ cell receptor, such as those required for metabolic reprogramming, cell division and cytokine production. These dynamic changes lead to marked remodelling of the functional $T$ follicular helper cell repertoire during the germinal centre reaction.

Humoral immunity and effective vaccination necessitate the development of high-affinity antibody-producing cells in germinal centres (GCs). These responses are regulated by $T$ follicular helper ($T_{FH}$) cells that express BCL6, the chemokine receptor CXCR5, high levels of PD-1, and $B$ cell trophic cytokines, each of which is required to orchestrate the GC reaction. Within GCs, limiting numbers of $T_{FH}$ cells interact with and select B cells on the basis of their ability to bind, internalize and present antigen as peptide complexed with major histocompatibility proteins (pMHC). Thus, the selection of B cells requires competition for limiting $T_{FH}$ cell signals\(^3,7\).

$B$ cells in the GC divide rapidly, hypermutate their antibody genes, and undergo affinity-based selection during the GC reaction. Productive contacts between $T_{FH}$ cells and GC B cells leads to increases in the $T_{FH}$ cell intracellular calcium concentration and the production of $B$ cell trophic interleukins. Whether these signalling events also lead to $T_{FH}$ cell proliferation, clonal selection and expansion within the GC has not been investigated\(^8\). To examine the kinetics of $T_{FH}$ cell development in response to antigens during the GC reaction, we immunized mice with 4-hydroxy-3-nitrophenylacetyl-ovalbumin (NP-OVA) (NP-OVA) (Fig. 1a, Extended Data Fig. 1a). Consistent with other reports\(^9,10,11,12,13\), $T_{FH}$ cells (CD4$^+$, CD62$^{lo}$, CD44$^{hi}$, CXCR5$^{hi}$, PD1$^{hi}$, BCL6$^+$) were first detected 4 to 5 days after immunization and expanded exponentially thereafter, reaching a peak at days 7–10, before contracting by day 21 (Fig. 1b).

Unlike most other effector $T$ cells, $T_{FH}$ cells are thought to be largely quiescent, in part because limiting the size of the GC $T_{FH}$ cell pool is required to maintain stringent B cell selection and prevent autoimmunity\(^14,15\). To explore whether $T_{FH}$ cells continue to divide once they have seeded the GC reaction, we tracked cell division by the incorporation of the thymidine analogue 5-ethynyl-2´-deoxyuridine (EdU) and intranuclear expression of Ki67 (Fig. 1c). We found that the proliferative profile of $T_{FH}$ cells paralleled that of GC B cells and was significantly ($P=0.001$ or $P<0.0001$) different from naive quiescent T cells. Proliferation peaked early, with a subsequent decrease to lower but significant levels of proliferation that persisted throughout the 19-day observation period (Fig. 1c). Similarly, 2–8% of $T_{FH}$ cells in chronic GCs in mesenteric lymph nodes and Peyer’s patches incorporated EdU (Fig. 1d).

To examine the extent of $T_{FH}$ cell proliferation over time, we tracked cell division using NP-OVA-immunized mice that express mCherry-labelled histone 2b (H2B–mCh) under the control of a doxycycline (DOX)-sensitive promoter (tTA-H2B-mCh mice)\(^16\). The tTA-H2B-mCh mice express H2B–mCh until they are exposed to DOX, at which point the expression of H2B–mCh is suppressed, enabling the dividing cells to dilute the indicator (Fig. 1e). Exposure of NP-OVA-immunized tTA-H2B-mCh mice to DOX over three days permits the integration of $T_{FH}$ cell division over time, as opposed to the instantaneous measurements provided by analysis of EdU incorporation or...
intranuclear Ki67 expression. On average, 27–30% of TFH cells in GCs diluted H2B–mCh in response to NP-OVA when exposed to DOX on days 7–10, 10–13 or 13–16 after immunization (Fig. 1f). By contrast, we found little or no detectable division by naive T cells in the same mice.

Naive T cells proliferate extensively after activation and during their differentiation into TFH cells. To ensure that the GC TFH cell proliferation was not exclusively derived from newly generated TFH cells, we used reporter mice that express tamoxifen-inducible Cre under the control of CD62L, which is expressed in naive T cells but not in TFH cells (Self-Cre<sup>T2</sup> ROSA-tdT mice) (Extended Data Fig. 2a–c). The administration of tamoxifen to immunized Self-Cre<sup>T2</sup> ROSA-tdT reporter mice fate maps naive T cells so that they can be distinguished from contemporaneous resident TFH cells if the naive cells are subsequently recruited to the GC (Extended Data Fig. 2d). Cell division was similar among recruited and resident TFH in indicator mice that were injected with tamoxifen 7 days after immunization as measured by EdU labelling on day 14 (Extended Data Fig. 2e).

The proliferative kinetics of TFH cells reflected the known decline in antigen availability in the days after immunization. To determine whether TFH cells undergo cell division in response to antigen, we used anti-DEC205 chimeric antibodies to deliver cognate OVA protein (anti-DEC–OVA) or an irrelevant parasite protein from <i>Plasmodium falciparum circumsporozoite</i> (anti-DEC–CS) to ongoing GC reactions (through binding to DEC205 receptors on GC B cells). C57BL/6 mice were immunized with NP-OVA and boosted by the injection of anti-DEC–OVA or anti-DEC–CS<sup>T2</sup> (Fig. 2a). EdU labelling 18 h after anti-DEC–OVA injection revealed antigen-dependent TFH cell proliferation (Fig. 2b).

Whereas 8% of TFH cells were labelled with EdU at this time point in the control mice treated with anti-DEC–CS, 17% were proliferating in the mice treated with anti-DEC–OVA (<i>P</i> < 0.0001).

Naive T cells proliferate in proportion to the strength of T cell receptor (TCR) signalling. Whether persistent TFH cell division is governed by the quality of TCR signalling has not been explored. Examining this in a polyclonal repertoire is challenging owing to the diversity and unknown constellation of TCR specificities that contribute to the TFH cell repertoire. To examine the role of TCR signalling to TFH cell proliferative responses, we used transgenic OT-II T cells that express a fixed receptor that can recognize OVA<sub>323–339</sub> with relatively high affinity while remaining differentially sensitive to a set of nested altered peptide ligands (APLs)<sup>19</sup> (Extended Data Fig. 3a). Here, the diminishing potency of each APL to elicit TCR signalling may be owing to differential loading onto MHC class II (altering the effective concentration of the ligand) or by altering TCR affinity, or both. Accordingly, OT-II T cells divide and differentiate into TFH cells in direct proportion to their ability to recognize and signal in response to the corresponding APL–pMHC ligands in vitro and in vivo<sup>19</sup> (Extended Data Fig. 3b–f). Thus, 46% of OT-II T cells became TFH cells 7 days following immunization with the high-signalling 4-hydroxyl-3-nitrophenylacetetyl–APL (NP–APL) as opposed to only 12% in response to low-signalling NP–APL immunization<sup>19</sup> (Extended Data Fig. 3e).

To determine whether the magnitude of the TCR signalling directly affected the degree of TFH cell cellular division during the GC reaction, as opposed to just pre-GC differentiation, we generated anti-DEC205–APL chimeric antibodies carrying either the high- or low-signalling APLs
Fig. 2 | Tfh cells proliferate proportionately to TCR signalling. a, Schematic representation of experimental setup used in b. Anti-DEC-high, anti-DEC-OVA323–339 or anti-DEC-low, anti-DEC-OVA323–339. b, Bar graph shows the percentage of proliferating Tfh cells as defined by EdU incorporation after treatment with anti-DEC–CS (10 mice) or anti-DEC–OVA (9 mice). Each dot represents an individual mouse. *P < 0.0001, unpaired Student’s t-test (two-tailed). c, Schematic representation of experimental setup used in d and e. Left, plots showing the percentage of OT-II Tfh cells that express Fucci (10, 10, 10 and 4 mice per group from left to right) or Ki67 (9, 10, 9 and 8 mice per group from left to right) 18 h after injection of anti-DEC205 chimeric antibody. Each dot represents an individual mouse. **P < 0.0001, ****P < 0.0001, one-way ANOVA test. Right, percentage of OT-II Tfh cells in anti-DEC323–339-boosted (switched) or un.injected (non switched). Data are from 10 or 16 mice per group and each dot represents one mouse. **P < 0.0001, unpaired two-tailed Student’s t-test. b, Bar graphs compare changes in the frequency of DO11.10 versus OT-I I Tfh cells in anti-DEC–OVA323–339-boosted (switched) or un injected controls (non switched). Data are from 10 or 16 mice per group and each dot represents one mouse. ****P < 0.0001, one-way ANOVA. c, Heat map of hierarchically clustered purified populations of OT-II Tfh cells. Comparing gene expression of the 50 most differentially expressed genes. *P < 0.0016, *P < 0.0211, ****P < 0.0001, ****P < 0.0001, one-way ANOVA. d, Schematic depicting experimental setup for the competition experiment between DO11.10 and OT-II Tfh cells in g. Bar graphs compare changes in the frequency of DO11.10 versus OT-II Tfh cells in anti-DEC–OVA323–339-boosted (switched) or un injected controls (non switched). Data are from 10 or 16 mice per group and each dot represents one mouse. ****P < 0.0001, unpaired two-tailed Student’s t-test. h, Bar graphs compare the size of blastng cells (left, forward scatter area (FSC)A, 8 mice per group) or the percentage of Ki67+ cells (right, 6 or 7 mice per group) in DO11.10 or OT-II Tfh cell populations 18 h after exposure to anti-DEC–OVA323–339 chimeric antibody. Each dot represents one mouse. *P < 0.0183, ****P < 0.0001, unpaired Student’s t-test. MFI, mean fluorescent intensity. i, Bar graph comparing expression of aCASP3 between non-boosted populations and in the same populations 18 h after anti-DEC–OVA323–339 boosting. ****P < 0.0001, ****P < 0.0001, one-way ANOVA test. Each experiment was performed two or three times; data are mean and s.e.m.
chimeric antibodies²¹. To confirm that the proliferation of T<sub>FH</sub> cells was driven by cognate interactions between T<sub>FH</sub> cells and GC B cells as opposed to cognate interactions between T<sub>FH</sub> and DCs, we limited anti-DEC205-boosting exclusively to B cells by adoptively transferring B1-8<sup>hi</sup> B cells and OT-II Fucci T cells into DEC205-deficient mice (Extended Data Fig. 3g). OT-II T<sub>FH</sub> Cells showed significant proliferation when antigen presentation was limited to GC B cells (P = 0.0048) (Extended Data Fig. 3h).

Next, to verify that the proliferating cells that responded to anti-DEC205 antibody boosting were GC-resident T<sub>FH</sub> cells, we used mice that carry a photoactivatable green fluorescent protein (OT-II paGFP<sup>+</sup>) and OT-II naive paGFP<sup>+</sup> T cells were transferred into NP-OVA-immunized C57BL/6 mice and subsequently injected with anti-DEC-OVA on day 10 after immunization, and GC-resident T<sub>FH</sub> cells were labelled by photoactivation 18 h later (Extended Data Fig. 4a–d). Flow cytometric analysis showed that 20% of GC (GFP<sup>+</sup>) T<sub>FH</sub> cells were in the S or G2M phases of the cell cycle (Extended Data Fig. 4e). Altogether, the data indicate that in addition to providing help, GC T<sub>FH</sub> cells can undergo proliferative expansion in response to pMHC presented in the GC.

To examine the transcriptional programs that are associated with TCR-driven T<sub>FH</sub> cell division, we performed mRNA sequencing (RNA-seq) on total OT-II T<sub>FH</sub> cells isolated 18 h after boosting with high or low anti-DEC–APLs, and non-boosted controls. Unsupervised hierarchical clustering segregated samples according to each condition and revealed a unique signature in the boosted OT-II T<sub>FH</sub> cells (Fig. 2e). Gene set enrichment analysis (GSEA) comparing T<sub>FH</sub> cells responding to high APLs versus non-boosted controls showed increased representation of pathways that regulate the cell cycle, metabolism, glycolysis and oxidative phosphorylation (Fig. 2e, Extended Data Fig. 5a). Comparison of the high and low APL groups revealed 533 differentially expressed genes, with an enrichment in cytokine and interleukin signalling in the high APL group, consistent with wider roles for TCR signalling in T<sub>FH</sub> cell function (Extended Data Fig. 5b). Altogether, the data indicate that T<sub>FH</sub> cells proliferate in direct proportion to their ability to recognize pMHC presented on GC B cells, and that this behaviour is sustained through a coordinated metabolic reprogramming.

High-affinity B cells outcompete their low-affinity counterparts during the GC reaction³⁴,³⁵,²⁵. We next investigated whether T<sub>FH</sub> cells also undergo clonal competition on the basis of their affinity for pMHC. To do so, we made use of two transgenic T cells that express OVA<sub>323–339</sub>, OVA<sub>327–339</sub> and OVA<sub>328–339</sub> (Extended Data Fig. 6b, c). The outgrowth of DO11.10 TFH cells, in response to boosting with an APL which increased its relative affinity compared with competitor OT-II T<sub>FH</sub> cells, was driven by cell proliferation as determined by an increase in cell size and Ki67 staining despite a concomitant increase in the expression of activated caspase-3 (aCASP3) (Fig. 2h, i, Extended Data Fig. 6g). We conclude that DO11.10 and OT-II TFH cells, albeit with their different genetic backgrounds withstanding, undergo competitive proliferative expansion in GCs of C57BL/6 × BALB/c F1 recipients with TCR-driven TFH cell division, we performed mRNA sequencing in the GC.

The numbers of T<sub>FH</sub> cells in the GC must be limiting to maintain stringent B cell selection³¹,³²,³³. Whether the quality of the T<sub>FH</sub> TCR repertoire also influences the products of the GC reactions remains to be determined. To examine how signals that induce the proliferative expansion of T<sub>FH</sub> cells might affect the quality of help provided to cognate B cells, we performed RNA-seq on purified, positively selected light-zone GC B cells 14 h after boosting with the anti-DEC–APLs (Extended Data Fig. 7a, b). Unsupervised hierarchical clustering separated the mRNAs obtained from B cells responding to control (non-boosted), and high and low anti-DEC–APLs into three distinct groups (Fig. 3b). Comparison of the differentially expressed genes showed that high-APL-boosted conditions induced higher levels of mRNAs associated with positive selection including MYC, mTORC1, MYC targets V2, Serpinf1, and Tgtp1. Additionally, the data indicate that T<sub>FH</sub> cells proliferate in direct proportion to their ability to recognize pMHC presented on GC B cells, and that this behaviour is sustained through a coordinated metabolic reprogramming.

**Fig. 3** TCR signalling dictates the quality of T cell help delivered. a, Schematic representation of experimental setup used in b, c. The flow cytometric plots showing the gating strategy to isolate positively selected light zone germinal centre B cells 14 h after injection of anti-DEC–APL antibody is shown in Extended Data Fig. 8. b, Heat map of hierarchically clustered purified populations of Fucci<sup>+</sup> light-zone B cells. The expression of the 50 most differentially expressed genes is compared. c, Graphical representation of GSEA and the rank-ordered gene lists found upregulated in recently selected Fucci<sup>+</sup> GC light-zone B cells that are boosted with anti-DEC-high versus anti-DEC-low chimeric antibodies. Nominal P = 0.0; enrichment score = 0.4911; normalized enrichment score (NES) = 2.64; false discovery rate (FDR) q = 0.0.
and cell division pathways than the non-boosted or low-APL-boosted conditions (*Fig. 3c, Extended Data Fig. 7b). Thus, the ability of the T cells to recognize cognate pMHC governs their ability to divide, the extent of trophic cytokine production and the magnitude of the selection signals provided to GC B cells.

Unlike GC B cells, TFH cells distribute among nascent GCs in lymph nodes and continue to emigrate between GCs during the immune response (*Fig. 3c, Extended Data Fig. 7b). Thus, the ability of the T cells to recognize cognate pMHC governs their ability to divide, the extent of trophic cytokine production and the magnitude of the selection signals provided to GC B cells.

To determine whether ‘polyclonal’ TFH cell clones also disseminate throughout GCs in the spleen, we compared their distribution in the two halves of spleens obtained 7 days after NP-OVA immunization (Extended Data Fig. 8a, b). As expected, TFH cell clones were shared and their relative distribution was similar between the two halves of the spleen as determined by TCR-α and TCR-β sequencing (Extended Data Fig. 8c).

To determine whether there is dynamic redistribution of TFH cell clones during a polyclonal immune response, we followed TFH cell clonotypes in the same mouse longitudinally by performing hemi-splenectomy during a polyclonal immune response1. To determine whether ‘polyclonal’ TFH cell clones also disseminate throughout GCs in the spleen, we compared their distribution in the two halves of spleens obtained 7 days after NP-OVA immunization (Extended Data Fig. 8a). As expected, TFH cell clones were shared and their relative distribution was similar between the two halves of the spleen as determined by TCR-α and TCR-β sequencing (Extended Data Fig. 8c).

To determine whether there are gene expression signatures associated with TFH cell clonal expansion or contraction, we analysed the transcriptome of single cells belonging to clones exhibiting these behaviours. Cells belonging to clones that expand or contract were segregated by principle component analysis (Fig. 4d). In agreement with the RNA-seq data obtained from OT-II TFH cells (Fig. 2e), gene set enrichment analysis (GSEA) revealed that the mRNAs expressed by clones that expand after day 7 differed from those that contracted, with the RNA-seq data obtained from OT-II TFH cells (Fig. 2e), gene set enrichment analysis (GSEA) revealed that the mRNAs expressed by clones that expand after day 7 differed from those that contracted. Downstream TCR signalling: nominal $P = 0.0029$; enrichment score = 0.37; NES = 1.84; FDR $q = 0.036$. Regulation of mitotic cell cycle: nominal $P = 0.00$; enrichment score = 0.63; NES = 2.71; FDR $q = 0.00$. Euler diagram comparing the number of shared genes between the scRNA-seq (grey) and OT-II bulk RNA-seq (white) that have the same behaviour, either up or downregulated (green).

and cell division pathways than the non-boosted or low-APL-boosted conditions (*Fig. 3c, Extended Data Fig. 7b). Thus, the ability of the T cells to recognize cognate pMHC governs their ability to divide, the extent of trophic cytokine production and the magnitude of the selection signals provided to GC B cells.

Unlike GC B cells, TFH cells distribute among nascent GCs in lymph nodes and continue to emigrate between GCs during the immune response1. To determine whether ‘polyclonal’ TFH cell clones also disseminate throughout GCs in the spleen, we compared their distribution in the two halves of spleens obtained 7 days after NP-OVA immunization (Extended Data Fig. 8a, b). As expected, TFH cell clones were shared and their relative distribution was similar between the two halves of the spleen as determined by TCR-α and TCR-β sequencing (Extended Data Fig. 8c).

To determine whether there is dynamic redistribution of TFH cell clones during a polyclonal immune response, we followed TFH cell clonotypes in the same mouse longitudinally by performing hemi-splenectomy on day 7 and then collecting the remaining half of the spleen on day 21 after immunization with NP-OVA, a procedure that did not measurably alter the size of the GC compartment per se (Fig. 4a, Extended Data Fig. 9a, b). To ensure that we assayed T cells entering spleen GCs de novo during the immunization period, we used Self-CreERT2 ROSA-tdT mice (Extended Data Figs. 2, 9d, e). Naive cells were labelled in reporter mice 5 days before immunization and TFH cells responding to the immunization were purified from hemi-splenectomized mice on days 7 and 21 based on tdTomato expression (Fig. 4a, Extended Data Fig. 10a). Single-cell RNA-seq (scRNA-seq) revealed a significant ($P < 0.001$) dynamic re-distribution of TFH cell clones between the two time points in all mice analysed (Fig. 4b, c, Extended Data Fig. 10b–d). TCR-α and TCR-β sequencing showed that 55% and 73% of all TFH cells were members of expanded clones on days 7 and 21, respectively. A total of 86% of the day 7 clones expanded or contracted between days 7 and 21, and only 13% were relatively conserved (examples noted by red, blue and green arrows in Fig. 4c).
between the clones that expanded or contracted after day 7 did so in parallel to the genes that were up- or downregulated within OT-II T<sub>FH</sub> cells in response to increased antigen presentation in the GC (Figs. 2e, 4f). We conclude that clones of T<sub>FH</sub> cells undergo considerable dynamic changes in response to antigen during polyclonal immune responses in the germinal centre.

The GC reaction is governed by T<sub>FH</sub> cells that select high-affinity B cells that present the highest levels of pMHC<sup>24</sup>. Although T cells cannot mutate their receptors and must remain limiting to maintain stringent B cell selection, our data indicate that ongoing T cell selection shapes T<sub>FH</sub> cell repertoires during the immune response<sup>37</sup>. Limiting numbers of T<sub>FH</sub> cells govern selection in the GC<sup>2,33–35</sup>. A paucity of T<sub>FH</sub> cells results in diminished antibody responses to viral infections in mice and macaques<sup>11–13</sup>. By contrast, overabundance of T<sub>FH</sub> cells interferes with affinity maturation and is associated with autoimmunity<sup>11,19</sup>. To maintain homeostasis, T<sub>FH</sub> cells are thought to limit their own proliferative responses to TCR stimulation by high-level expression of negative regulators such as PD1, SLAMF6 and LAG<sup>12,13,29</sup>. Nevertheless, T<sub>FH</sub> cells remain sufficiently responsive to pMHC to provide help to cognate B cells in the form of trophic cytokines. Our data indicate that in addition to triggering T cell help, interaction between T<sub>FH</sub> cells and cognate pMHCII on GC B cells also favours affinity-based selection of T<sub>FH</sub> cells in the GC.

Selection of T<sub>FH</sub> cells with increased sensitivity to pMHC across GCs during the reaction is likely to prolong the immune response in the face of ever decreasing amounts of antigen. In addition, enhanced TCR signalling by affinity-selected T<sub>FH</sub> cells may account for increased production of plasma cells in the later stages of the GC reaction<sup>36</sup>. In conclusion, the clonal dynamics that govern the relationship between GC B cells and T<sub>FH</sub> cells is even more dynamic and symbiotic than previously envisaged.

**Online content**

Any methods, additional references, Nature Research reporting summaries, source data, extended data, supplementary information, acknowledgements, peer review information; details of author contributions and competing interests; and statements of data and code availability are available at https://doi.org/10.1038/s41586-021-03187-x.

1. Shulman, Z. et al. T follicular helper cell dynamics in germinal centers. Science 341, 673–677 (2013).
2. Schwickert, T. A. et al. A dynamic T cell-limited checkpoint regulates affinity-dependent B cell entry into the germinal center. J. Exp. Med. 208, 1243–1252 (2011).
3. Crotty, S. T follicular helper cell biology: a decade of discovery and diseases. Immunity 50, 1132–1148 (2018).
4. Vinuesa, C. G., Linterman, M. A., Yu, D. & MacLennan, I. C. M. Follicular helper T cells. Annu. Rev. Immunol. 34, 335–368 (2016).
5. Cyster, J. G. & Allen, C. D. C. B cell responses: cell interaction dynamics and decisions. Cell 177, 524–540 (2019).
6. Victora, G. D. & Nussenzweig, M. C. Germinal centers. Annu. Rev. Immunol. 30, 429–457 (2012).
7. Pratama, A. & Vinuesa, C. G. Control of TFH cell numbers: why and how? Immunol. Cell Biol. 92, 40–48 (2014).
8. Shulman, Z. et al. Dynamic signaling by T follicular helper cells during germinal center B cell selection. Science 345, 1058–1062 (2014).
9. Kitano, M. et al. BCL6 protein expression shapes pre-germinal center B cell dynamics and follicular helper T cell heterogeneity. Immunity 34, 961–972 (2011).
10. Crotty, S. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29, 621–663 (2011).
11. Linterman, M. A. et al. Follicular helper T cells are required for systemic autoimmunity. J. Exp. Med. 206, 561–576 (2009).
12. Cubas, R. A. et al. Inadequate T follicular cell help impairs B cell immunity during HIV infection. Nat. Med. 19, 494–499 (2013).
13. Harker, J. A., Lewis, G. M., Mack, L. & Zuniga, E. I. Late interleukin-6 escalates T follicular helper cell responses and controls a chronic viral infection. Science 334, 825–829 (2011).
14. Fahey, L. M. et al. Viral persistence redirects CD4 T cell differentiation toward T follicular helper cells. J. Exp. Med. 208, 987–999 (2011).
15. Loci, M. et al. Human circulating PD-1<sup>+</sup>CXCR3<sup>+</sup>CXCR5<sup>+</sup> memory T<sub>FH</sub> cells are highly functional and correlate with broadly neutralizing HIV antibody responses. Immunity 39, 758–769 (2013).
16. Gittin, A. D., Shulman, Z. & Nussenzweig, M. C. Clonal selection in the germinal centre by regulated proliferation and hypermutation. Nature 505, 637–640 (2014).
17. Gittin, A. D. et al. T cell help controls the speed of the cell cycle in germinal center B cells. Science 349, 643–646 (2015).
18. Hawiger, D. et al. Dendritic cells induce peripheral T cell unresponsiveness under steady state conditions in vivo. J. Exp. Med. 194, 769–779 (2001).
19. Robertson, J. M. Jensen, P. E. & Eavold, B. D. OT-I and OT-II T cells recognize a C-terminal ovalbumin 323–339 epitope. J. Immunol. 164, 4706–4712 (2000).
20. Tubo, N. J. et al. Single naive CD4+ T cells from a diverse repertoire produce different effector cell types during infection. Cell 153, 785–796 (2013).
21. Sakaua-Sawano, A. et al. Visualizing spatiotemporal dynamics of multicellular cell-cycle progression. Cell 132, 487–498 (2008).
22. Aiba, Y. et al. Preferential localization of IgG memory B cells adjacent to contracted germinal centers. Proc. Natl Acad. Sci. USA 107, 12192–12197 (2010).
23. Jiang, W. et al. The receptor DEC-205 expressed by dendritic cells and thymic epithelial cells is involved in antigen processing. Nature 375, 151–155 (1995).
24. Victoria, G. D. et al. Germinal center dynamics revealed by multiphoton microscopy with a photoactivatable fluorescent reporter. Cell 143, 592–605 (2010).
25. Patterson, G. H. & Lippincott-Schwartz, J. A photoactivatable GFP for selective photolabeling of proteins and cells. Science 297, 1873–1877 (2002).
26. Lau, A. W. & Brink, R. Selection in the germinal center. Curr. Opin. Immunol. 63, 29–34 (2020).
27. Barnden, M. J., Allison, J., Heath, W. R. & Carbone, F. R. Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements. Immunol. Cell Biol. 76, 34–40 (1998).
28. Hu, J., Qi, G. & August, A. Itk derived signals regulate the expression of Th-POK and controls the development of CD4 T cells. PLoS ONE 5, e8891 (2010).
29. Crotty, S. T follicular helper cell differentiation, function, and roles in disease. Immunity 41, 529–542 (2014).
30. Vinuesa, C. G., Tangye, S. G., Moser, B. & Mackay, C. R. Follicular B helper T cells in antibody responses and autoimmunity. Nat. Rev. Immunol. 8, 853–865 (2005).
31. Finkin, S., Hartweger, H., Olivera, T. Y., Kara, E. E. & Nussenzweig, M. C. Protein amounts of the MYC transcription factor determine germinal center B cell division capacity. Immunity 51, 324–336.e5 (2019).
32. Markenschlager, J. et al. Stepwise B-cell-dependent expansion of T helper clonotypes diversifies the T-cell response. Nat. Commun. 7, 10281 (2016).
33. de Vinuesa, C. G. et al. Germinal centers without T cells. J. Exp. Med. 191, 485–494 (2000).
34. Johnston, R. J. et al. Bcl6 and Blimp-1 are reciprocal and antagonistic regulators of T follicular helper cell differentiation. Science 325, 1006–1010 (2009).
35. Rolf, J. et al. Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction. J. Immunol. 185, 4042–4052 (2010).
36. Wessel, F. J., Zuccarino-Catana, G. V., Chikina, M. & Shlomchik, M. J. A Temporal switch in the germinal center determines differential output of memory B and plasma cells. Immunity 44, 116–130 (2016).

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

© The Author(s), under exclusive licence to Springer Nature Limited 2021
Article

Methods

**Mice**

Mice were housed at a temperature of 72 °F (22 °C) and humidity of 30–70% in a 12-h light/dark cycle with ad libitum access to food and water. Male and female mice aged 8–10 weeks at the start of the experiment were used throughout. C57BL/6J, BALB/c, OT-II (C57BL/6J) and DOI11.10 (BALB/c) mice were purchased from Jackson Laboratories. Fucci transgenic mice were obtained from T. Kuroskai and A. Miyawaki. C7 mice were obtained from the S. Rudensky laboratory. OT-II Fucci, tTa-H2B–mCh mice, OT-II pA2FP and DEC205ε (also known as Ly75tm1Mnz) were generated and maintained at Rockefeller University.

**Immunizations and treatments**

C57BL/6J, Sell-CreERT2 ROSA-tdTom, C7, tTa-H2B-mCh mice or F,, recipient mice (6–12 weeks old) were immunized with 20 μg or 50 μg of NP17–OVA (Bioresearch Technologies) precipitated in alum in footpads or intraperitoneally respectively. For NP–APL immunizations, 100 μl of each hapten was precipitated in alum at a 2:1 ratio and injected into footpads.

**Anti-DEC–OVA, anti-DEC–CS and anti-DEC–APL chimeric antibodies:**

Anti-DEC–OVA, anti-DEC–CS and anti-DEC–APL chimeric antibodies were transiently expressed in 293–6E cells using polyethylenimine (PEI, Sigma 408727) for transfection. The supernatant was collected 7 days later and the chimeric antibodies were concentrated by ammonium sulfate precipitation. After centrifugation the pellet was resuspended in PBS and affinity purified on Protein G columns (Protein G Sepharose 4 Fast Flow, 17-0618-05, GE Healthcare).

**Hemi-splenectomy**

Mice were kept on antibiotics prior to immunization as prophylaxis against infection after surgical intervention. On day 7 after immunization, mice were anaesthetized with isoflurane. The left side of the mouse was shaved and cleaned before an incision was made in the skin followed by a smaller incision in the peritoneal wall to allow access to the spleen. The section of spleen to be removed was tied off by using sutures to prevent bleeding, and then cut out while leaving the splenic artery intact. The peritoneal wall was closed and stitched using perma-hand silk 5-0 sutures (Ethicon). The skin was closed using 9 mm wound clips (Clay Adams brand, Becton Dickinson). After recovery from anaesthesia, mice were transferred to a new clean cage with a heating pad.

**T cell culture and transfer**

Single-cell suspensions were prepared from the spleens and lymph nodes of donor mice. CD4+ T cells were enriched using immunomagnetic negative selection (StemCell Technologies). For adoptive transfer experiments 0.5 × 10^9–1 × 10^10 CD4+ T cells were injected into recipient mice by intravenous injection.

**Peptide synthesis**

The peptides were created using a Protein Technologies Symphony peptide synthesizer on pre-coupled Fmoc-Lysine(e-biotinyl)-OH Wang resins (Bachem). Reactions were conducted at a 100-μM scale and elongated using 9-fluorenylmethoxycarbonyl (Fmoc)-protected amino acids. Deprotection of the amine was accomplished with 20% piperidine in NMP (N,N-diisopropylethylamine). Repetitive coupling reactions were conducted using 0.3 M HATU in CHCl3 and 0.6 M DIEA using NMP as the primary solvent.

The peptides were capped at amine terminus with a 4-hydroxy-3-nitrophenyl acetic acid label. Resin cleavage and side-chain deprotection was achieved by transferring beads to a 100 ml round bottom flask which are then reacted (room temperature in fume hood) with 8.0 ml concentrated, sequencing grade, trifluoroacetic acid including a scavenger mixture of triisopropylsilane and degassed water, in a ratio of 94:3:3 over 6 h. Column filtration removed the resin, dispensing it into a 50-ml round bottom flask. The TFA/peptide solution volume was then reduced to 2 ml through these of a rotary evaporator. A standard ether precipitation was conducted on the peptides by transferring the solution to a 50 ml falcion tube containing 40 ml of cold TBME (tert-butil methyl ether). Tube was then placed in an ice bath for 2 h to aid in precipitation, followed by pelation formation using centrifugation (3,300 rpm for 5 min). Excess ether was removed by vacuum aspiration and the peptide pellet was then allowed to dry overnight in a fume hood. Peptide was then dissolved in 20% acetonitrile and 10 ml HPLC grade water, subsampled for liquid chromatography–mass spectrometry (LC–MS) and lyophilized. This crude product was analysed by reversed-phase Aquity UPLC using a Waters BEH C18 column and monitoring 220 nm absorbance. Peptide integrity was simultaneously verified by a capillary split flow into a tandem electrospray mass spectrometer using a Thermofinnigan LTQ system. Preparative chromatography purification was accomplished on a Vydac C18RP preparative column on a Waters 600 Prep HPLC. Fractions are collected in 30 s intervals, with each characterized using LC–MS on the above system and the fractions containing desired product are then lyophilized, weighed and provided to Nussenzweig laboratory.

**B cell transfer**

Single-cell suspensions were prepared from the spleens and lymph nodes of donor mice. Resting B cell suspensions were enriched using immunomagnetic positive selection using CD43 (StemCell Technologies). Approximately 5 × 10^7 Bi8’ B cells (5 × 10^7 IgA+, NP-specific B cells) composed of the indicated populations were injected into recipient mice by intravenous injection.

**T cell activation in vitro**

Peritoneal macrophages or B cells were collected and plated in flat bottomed 96-well plates as a source of antigen-presenting cells. On the next day, CD4 + T cells were enriched from spleens by magnetic bead selection (StemCell Technologies) and labelled with CTV. Approximately 100,000 CTV-labelled or unlabelled cells were then co-cultured with the antigen-presenting cells and the indicated amount of the APLs and T cell activation was assessed 18 h later by flow cytometry.

**T cell activation in vivo**

CD4+ T cells were enriched from spleens by magnetic bead selection (StemCell Technologies) and labelled with CTV. CTV labelled cells were then injected into mice and the quality of the T-cell response assessed 3–7 days later by flow cytometry.

**Flow cytometry**

Single-cell suspensions were stained with antibodies directly conjugated to surface markers. Intracellular stains were performed using
commercially available Fix and permeabilization solutions coupled to incubation with ki67, aCASP3 or DAPI antibodies. Multi-colour cytometry was performed on the Symphony flow cytometer (BD biosciences) and analysed with FlowJo v10.4.2.

Photoactivation
To label light-zone-resident follicular dendritic cells, 10 μl of 1 mg ml⁻¹ of B-phycocerythrin (Invitrogen) was mixed with 1 μl of 10 mg ml⁻¹ rabbit anti-PE (Thermo) and injected into pre-immunized mice, 2 days before imaging. Lymph nodes were collected and then cleared of adipose tissue under a dissecting microscope and placed in PBS between two coverslips held together by vacuum grease. FDC networks were identified by imaging at λ = 950 nm, at which no photoactivation is observed, and 3D regions of interest were photoactivated by higher-power scanning at λ = 830 nm. Imaging experiments were performed using an Olympus FV1000 upright microscope fitted with a 25× 1.05 NA Plan water-immersion objective and a Mai-Tai DeepSee Ti-Sapphire laser (Spectraphysics).

RNA sequencing
For bulk RNA-seq experiments, congenic OT-II Tfh cells (CD4⁺, CD62⁻⁺, CXCR5⁺, PD-1⁻⁺) or positively selected B cells (500 cells) were purified by flow cytometry 18 h after pre-immunized host mice were injected with anti-DEC205 chimeric antibodies. One nanogram of total RNA was used to generate full-length cDNA using Clontech’s SMART-Seq v4 Ultra Low Input RNA Kit (634888). The cDNA was used to prepare libraries using Illumina Nextera XT DNA sample preparation kit (FC-131-1024). Libraries with unique barcodes were pooled at equal molar ratios and sequenced on an Illumina NextSeq 500 sequencer to produce 75-bp reads, following manufacture protocol (15048776).

For scRNA-seq, single-cell suspensions were prepared from half-spleens of NP-OVA immunized Sell-CreERT2 ROSA-tdt mice on days 7 and 21 after immunization. Samples were indexed with TotalSeqC (BioLegend) cell surface antibodies and CD4⁺, CD62⁻⁺, CD44⁺, PD1⁻⁻, CXCR5⁻⁻, tdTomato⁺ Tfh cells were purified by flow cytometry, pooled and loaded onto a Chromium Controller (10x Genomics). Single-cell RNA-seq libraries were prepared using the Chromium Single Cell 5’ v2 Reagent Kit (10x Genomics) according to manufacturer’s protocol. Libraries were loaded onto an Illumina NextSeq with the mid-Output Kit (150 paired end) for V-D-J analysis or Novaseq for single-cell gene expression. Hashtag indexing was used to demultiplex the sequencing data and generate gene-barcode matrices, respectively.

Statistical analyses
Statistical tests were conducted using Prism (GraphPad) software. Unpaired, two-tailed Student’s t-tests and one-way ANOVA with Tukey’s post hoc tests to further examine pairwise differences were used. Data were considered statistically significant at *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, and ****P ≤ 0.0001. The number of mice per group, number of replicates and the nature of error bars are indicated in the legend of each figure. Centre bars always indicate mean and error bars denote s.e.m.

Computational analysis
For differential gene expression analysis in the bulk RNA-seq experiments we used kallisto (v.0.46) to map sequence reads to Mus musculus transcriptome (GRCm38/ Ensembl release 99). Kallisto TPM values were converted to absolute counts using tximport (v.1.12.3) R package and DESeq2 (v.1.24.0) was used for differential expression analysis. Differentially expressed genes were defined by having an adjusted P < 0.05 and |log2FC| > 1.5 in the Venn diagrams common differentially expressed genes also had common behaviour between groups, that is, up and down between the two data sets. Hierarchical clustering was based on combined data from three experimental repeats. Hierarchical clustering done based on data from the individual repeats gave similar results.

For single-cell RNA-seq analysis we used Cell Ranger (v.3.0.2) 10x Genomics for single-cell UMI quantification and TCR clonotype assembly. Hashtag oligos (HTOs) UMI counts were processed using CITE-Seq-Count (v.1.4.0). We used Seurat (v.3.1.2), an R package to analyse single-cell RNA-seq data, to identify differentially expressed genes. Genes expressed in at least 10% of all cells belonging to clones exhibiting expansion or contraction, with the adjusted P-value by Bonferroni correction less than 0.05 and with |average log2FC| > 1.1 were selected as statistically significant differentially expressed genes.

To define Tfh cell clonal behaviours, we used multiple binomial tests to interrogate whether the frequency of cells of a specific clone in the second time point is greater or less than expected, according to the frequency of the same clone in the first time point. Adjusted P-values (q-value) were calculated using the FDR correction. Expanded clones were defined as having cell frequency greater than expected in the second time point (q < 0.05), while contracted clones were defined as having cell frequency less than expected in the second time point (q < 0.05). Clones without statistical significance for any test were classified as conserved clones.

Ethical statement
All procedures in mice were performed in accordance to protocols approved by the Rockefeller University IACUC. All animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committee of NIAID, NIH.

Antibodies
Lists of monoclonal antibodies produced and their characteristics are in Supplementary Table 1.

Data availability
The data discussed in this publication have been deposited in the NCBI Gene Expression Omnibus are accessible through GEO series accession number GSE147182.

Acknowledgements We thank A. Miyawaki and T. Kurosaki for the Fucci mice, E. E. Kara and T. Haggblad for the generation and maintenance of Sell-CreERT2 ROSA-tdt reporter mice, H. Zebrowski for the generation of the APLs and the NP-APL conjugates in house, T. Eisenreich for help with mouse colony management, and technical help. A. Escolano for advice. B. Zhang and C. Zhao at The Rockefeller University Genomics Resource Center for assistance with 10x genomics and high-throughput sequencing. K. Gordon and K. Chhosphel for assistance with mouse colony management, and technical help, A. Escolano for advice, B. Zhang and C. Zhao at The Rockefeller University Genomics Resource Center for assistance with 10x genomics and high-throughput sequencing. K. Gordon and K. Chhosphel for assistance with cell sorting, and all members of the Nussenzweig laboratory for discussions. We thank G. Victoria for discussions involving the photoactivation experiments. This work was supported by National Institutes of Health (NIH) grant 5R01 AI037528 and NIH Center for AIDS Research (NCCR) of the AIDS Vaccine Immunology and Immunogen Discovery (CHAVID) U15 AI144462-01 to M.C.N. J.M. is an EMBO fellow. M.C.N. is an HHMI investigator.

Author contributions J.M., S.F. and M.C.N. conceived, designed and analysed the experiments. J.M., S.F. and J.K. carried out all experiments. A.G. and M.C. produced anti-DEC205 conjugates. C.R.N. contributed to paGFP experiments and discussions. H.H. bred and helped generate the Sell-CreERT2 ROSA-tdt mice. V.R. and T.Y.O. performed the bioinformatic analysis. B.T.C., W.Z. and P.D.O. helped perform the characterization of APL, MHC class II occupancy. J.M. and M.C.N. wrote the manuscript with input from all co-authors.

Competing interests The authors declare no competing interests.

Additional information
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41586-021-03187-x. Correspondence and requests for materials should be addressed to J.M.

Peer review information Nature thanks the anonymous, reviewer(s) for their contribution to the peer review of this work.

Reprints and permissions information is available at http://www.nature.com/reprints.
Extended Data Fig. 1 | T<sub>FH</sub> cell gating strategy. a, Flow cytometry plots detailing the T<sub>FH</sub> cell gating strategy. Rightmost histogram compares BCL6 expression in naive (grey) and non T<sub>FH</sub> (blue) versus T<sub>FH</sub> (red) cell populations on day 10 after immunization.
Extended Data Fig. 2 | Production of Sell-CreERT2 ROSA-tdT indicator mice. 

a, Targeting strategy and the configuration of the SellIRES-CreERT2 allele. The mice were produced at Rockefeller University and crossed to ROSA tdTomato loxP/loxP to generate Sell-CreERT2 ROSA-tdT indicator mice. 

b, Schematic representation of the experimental setup. 

c, Flow cytometry plots profiling tdTomato expression in naive and Tm+ cell splenic compartments in tamoxifen treated mice culled 4 dpi. Rightmost plots compare the percentage of tdTomato labelling in naive T cells (red) and Tm+ cells (blue) residing in spleens (closed circle) or lymph nodes (open circle) of mice following the regime outlined in b. Data are from 4–5 mice per group and each dot represents one mouse. ****P < 0.0001, one-way ANOVA test. The experiment was performed twice. 

d, Schematic representation of the experimental setup. 

e, Flow cytometry plot showing EdU incorporation in labelled (red) or unlabelled (grey) Tm+ cell populations on 14 dpi. Rightmost plots show the frequency of EdU+ Tm+ cells at 14 dpi, in population generated in the first 7 days (grey) or 8 and 14 from day 7 onwards (red) or the cumulative (blue). EdU was administered 3h before mice were culled. Numbers inside the gates denote the relative representation of EdU+ cells from within tdTomato+ or tdTomato− populations. Each dot represents one mouse. Data are from 14 mice and the experiment was performed twice.
Extended Data Fig. 3 | OT-II have disparate abilities to recognize the truncated APLs. a, Description and sequence alignment of the nested APLs. b, Graph shows OT-II T cell responses to decreasing concentrations of APLs in vitro as measured by CD69 upregulation after 18 h of exposure. Bar graph shows the area under the adjacent response curves (AUC). \( P = 0.0130, \quad *** P = 0.0001, \quad **** P < 0.0001 \), one-way ANOVA test. Each dot represents a distinct experimental well. This experiment was repeated four times. c, Schematic representation of experimental setup used in d-f. d, Bar graph shows percentage of OT-II among all CD4 T cells in adoptive transfer recipients 72 h after immunization with the indicated NP-APLs. e, Bar graph shows percentage of OT-II T cells that become TFH cells 7 days after NP-APL immunization. \( * P = 0.0186, \quad ** P = 0.0039, \quad *** P < 0.001, \quad **** P < 0.0001 \), one-way ANOVA test. Each dot represents one mouse, with 6 or 7 mice per group and repeated twice. f, Flow cytometry plots showing dilution of CellTrace Violet by OT-II T cells responding to the NP-APL immunization in vivo after 72 h. Each plot is an individual mouse. g, Schematic representation of experimental setup used in h. h, Left, flow cytometry plots profiling Fucci expression in non-boosted (5 mice) control or 18 h after anti-DEC–OVA (7 mice) injection. Right, comparison of the percentage of Fucci+ OT-II TFH cells in the respective conditions. Each dot represents a mouse and this experiment was performed twice. \( ** P = 0.0048 \), unpaired Student’s t-test.
Extended Data Fig. 4 | GC-resident T<sub>fh</sub> cells proliferate.  

**a.** Schematic representation of experimental set up used in **b–e.** **b,** GCs in popliteal lymph nodes, as defined by the fluorescently labelled FDC network (red), were photoactivated (green) 18 h after anti-DEC–OVA injection, stained with a cocktail of fluorescent antibodies to allow analysis by downstream flow cytometry. **c,** Representative flow cytometry plots showing the gating of photoactivated OT-II T<sub>fh</sub> cells. **d,** A single GC from a popliteal lymph node as defined by fluorescently labelled FDC networks (red) before and after photoactivation (left to right, respectively). OT-II GC resident T<sub>fh</sub> cells were photoactivated (green) 18 h after anti-DEC–OVA injection. **e,** Representative flow cytometry plots comparing DAPI staining in host (grey) or OT-II GC-resident GFP<sup>+</sup> cells (green) in unperturbed mice (left) or 18 h after boosting with an anti-DEC–OVA injection (right). Bar graph shows the percentage of photoactivated OT-II T<sub>fh</sub> cells that entered the cell cycle (DAPI<sup>+</sup>) after anti-DEC–OVA injection (5 mice) or in uninjected controls (3 mice). Each dot represents pooled lymph nodes from a single mouse. **P** = 0.0086, unpaired Student’s *t*-test. This experiment was repeated twice.
Extended Data Fig. 5 | Increased TCR signalling enforces proliferation supported by a switch in metabolic status. a, b, GSEA and the rank-ordered gene lists found upregulated in anti-DEC-high versus non-boosted (a) or anti-DEC-high versus anti-DEC-low (b) groups. Nominal *P* values are indicated.
Extended Data Fig. 6 | DO11 and OT-II have different affinities for APLs. a, Schematic depicts the experimental setup. CTV-labelled DO11.10 and OT-II T cells were adoptively transferred into F1 mice and subsequently immunized with the NP-APLs. b, Representative flow cytometry plots compare the relative distribution and CellTrace Violet dilution of DO11.10 and OT-II T cells in adoptive transfer recipients at 3 dpi. Each panel of plots represents an individual mouse from the group. c, Bar graph shows the aggregate relative contribution of DO11.10 and OT-II T cells 3 days after immunization in 3 mice per condition. Dotted line depicts the input ratio of DO11.10 and OT-II at the time of transfer. ***P < 0.0007, ****P < 0.0001, unpaired Student's t-test. This experiment was performed twice but data for one experiment are plotted. d, Schematic depicting experiment in which adoptive transfer recipients of DO11.10 and OT-II T cells were immunized with NP-329-339. Adjacent bar graph compares changes in the frequency of DO11.10 versus OT-II TFH cells when boosted with different anti-DEC205 chimeric antibodies. Bar graph compares changes in the frequency of DO11.10 versus OT-II TFH cells when boosted with different anti-DEC205 chimeric antibodies at 6 dpi. Each dot represents an individual mouse and group size varied from 3–13 mice per condition. ns, not significant (P = 0.9). **P < 0.01, ***P < 0.001, one-way ANOVA test. e, Representative flow cytometry plots showing the distribution of DO11.10 and OT-II T cells in the T FH cell compartment 6 days after immunization. f, Schematic depicting experiment in which adoptive transfer recipients of DO11.10 and OT-II T cells were immunized with NP-329-339 and boosted with the respective anti-DEC205 chimeric antibodies. Bar graph compares changes in the frequency of DO11.10 versus OT-II TFH cells when boosted with different anti-DEC205 chimeric antibodies at 6 dpi. Each dot represents an individual mouse and group size varied from 3–13 mice per condition. ns, not significant (P = 0.9). **P < 0.01, ***P < 0.001, one-way ANOVA test. g, Histogram overlays compare cell size (FSC-A), Ki67 expression and aCASP3 expression in OT-II and DO11.10 TFH cell populations from individual mice 18 h after anti-DEC-OVA323-339 boosting. These experiments were repeated two or three times.
Extended Data Fig. 7 | TCR signalling dictates the quality of T cell help delivered to cognate B cells. a, Flow cytometric plots showing the gating strategy to isolate positively selected light-zone germinal centre B cells 14 h after anti-DEC–APL antibody injection. b, Top, graphical representation of GSEA and the rank-ordered gene lists found upregulated in anti-DEC-high boosted versus anti-DEC-low boosted and recently selected Fucci+ GC light zone B cells. Bottom, graphical representation of GSEA and the rank-ordered gene lists found upregulated in anti-DEC-high boosted versus non-boosted controls. Nominal P values are indicated.
Extended Data Fig. 8 | Conservation of T<sub>H</sub> cell clonal families and clonal dominance in the spleens of day-7 immunized mice. a, Schematic representation of the experimental strategy used in b, c. b, Flow cytometric plots depict the gating strategy used to define T<sub>H</sub> cell populations in c. In brief, wild-type mice were immunized with NP-OVA, and 7 days later T<sub>H</sub> cells were purified from the two halves of the spleen and then sequenced. c, Pie charts show expanded clonal families in each half of the spleen. Slices are proportional to the number of clones within a family. Colours indicate shared clonotypes (cells that share the same CDR3 sequence for alpha or/and beta chains) between the two spleen halves, ‘a’ and ‘b’, from an individual mouse. Grey tones indicate unique clones not shared between the two halves. The total number of paired TCR chains recovered is indicated by the number in the centre of the pie charts. Clonal distribution between adjacent spleen halves in mouse 1 (M1) (top) (not significant, *P* = 0.2279) and mouse 2 (M2) (bottom, *P* = 0.009), Fisher’s exact test. Adjacent bar graphs show the relative conservation of clonotypes between the two halves of the spleen. ‘Shared’ refers to a clone found in both segments of the spleen; ‘non-shared’ refers to anatomically novel clones.
Extended Data Fig. 9 | Hemi-splenectomized mice have normal GC reactions. a, Schematic representation of the experimental strategy used in b. b, In brief, NP-OVA-immunized C57BL/6 mice were biopsied on 7 dpi and culled on 14 dpi to interrogate changes that might occur in the GC compartment after surgical intervention (left). NP-OVA-immunized C57BL/6 mice who did not receive surgical intervention served as controls for biopsied mice (right). b, Adjacent plots show the frequency of T<sub>FH</sub> cells within total CD4<sup>+</sup> T cells (left) or GC B cells within total B cells (right) in individual biopsied mice between time points 7 dpi (open purple) and 14 dpi (closed purple). P = 0.43 (left) and P = 0.14 (right), paired Student's t-test. Dotted lines trace individual mice over time. c, Adjacent plots compare the frequency of T<sub>FH</sub> cells within total CD4<sup>+</sup> T cells (left) or GC B cells within total B cells (right) at 14 dpi in mice that were biopsied (purple) or C57BL/6 mice that were not (black). P = 0.52 (left), P = 0.13 (right), Student's t-test. d, Schematic representation of the experimental strategy used in e, e, Flow cytometry plots profiling of tdTomato expression in splenic naive and T<sub>FH</sub> cell compartments in tamoxifen-treated mice but unimmunized mice (left) or similarly in tamoxifen treated mice 7 days after NP-OVA immunization (right). Rightmost bar graph compares the percentage of tdTomato<sup>+</sup> populations between labelled populations in the unimmunized and immunized mice (12 days after tamoxifen administration and 7 dpi).
Extended Data Fig. 10 | scRNA-seq reveals extensive clonal evolution of \( \text{TH} \) cells. **a**, Flow cytometry plots depicting gating strategy used to define responding \( \text{TH} \) cells. **b**, Schematic representation of the experimental strategy used in **d**. **c**, Colour-coded indexing for the clonal behaviours categorized in mice between days 7 and 21. Expanded (red), conserved (green), contracted (blue) and singles (grey). Clones that are not coloured were novel to each time point. **d**, Pie charts show clonal populations of \( \text{TH} \) cells within each mouse at each time point. Segments within the pie charts report the proportional representation of each clone. Clonotypes contain the same CDR3 sequence for alpha or beta chains. Clonal composition is significantly different between time points within the same mouse. ****\( P = 0.000016 \), Fisher exact test. Numbers inside the pie charts refer to the total number of TCR-\( \alpha \) and TCR-\( \beta \) sequences recovered.
Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see Authors & Referees and the Editorial Policy Checklist.

Statistics

For all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.

- n/a
- The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
- A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
- The statistical test(s) used AND whether they are one- or two-sided
- A description of all covariates tested
- A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
- A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
- For null hypothesis testing, the test statistic (e.g. F, t, r) with confidence intervals, effect sizes, degrees of freedom and P value noted
- Give P values as exact values whenever suitable.
- For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
- For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
- Estimates of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated

Our web collection on statistics for biologists contains articles on many of the points above.

Software and code

Policy information about availability of computer code

Data collection
Flow cytometry data was collected using FACDIVA version 8.0.2.

Data analysis
MacVector was used for sequence analysis. Graph Prism 7 was used for data analysis and for graph generation. In addition, We used cellranger (v3.0.2) from 10X Genomics for single-cell UMI quantification and TCR clonotype assembly. We used Seurat (v3.1.2) an R package to analyze single cell RNA-seq data and to identify differentially expressed genes; graphs were created using R language. For bulk-RNA seq analysis we used kallisto (v.0.46) to map sequence reads to Mus musculus transcriptome (GRCm38/ Ensembl release 99). Kallisto TPM values were converted to absolute counts using tximport (v1.12.3) R package and DESeq2 (v.1.24.0). For differential gene expression analysis in the bulk RNA sequencing experiments we used kallisto (v.0.46) to map sequence reads to Mus musculus transcriptome (GRCm38/ Ensembl release 99). Kallisto TPM values were converted to absolute counts using tximport (v1.12.3) R package and DESeq2 (v.1.24.0) 1 was utilized for differential expression analysis. Differentially expressed genes were defined by having an adjusted p-value < 0.05 and | logFC| > log2(1.5). Im the Venn diagrams common differentially expressed genes also had common behaviour between groups. ie up and down between the two data sets. Hierarchical clustering was based on combined data from three experimental repeats. Hierarchical clustering done based on data from the individual repeats gave similar results.

For Single-cell RNA-Seq analysis we used cellranger (v3.0.2) 10X Genomics for single-cell UMI quantification and TCR clonotype assembly. Hashtags oligos (HTOs) UMI counts were processed using CITE-Seq-Count (v1.4.0). We used Seurat (v3.1.2) 2,3, an R package to analyze single cell RNA-seq data, to identify differentially expressed genes. Genes expressed in at least 10 percent of all cells belonging to clones exhibiting expansion or contraction, with the adjusted p-value by Bonferroni correction less than 0.05 and with |average logeFC| > loge(1.1) were selected as statistical significant differentially expressed genes. To define Tfh clonal behaviors we used multiple binomial tests to interrogate whether the frequency of cells of a specific clone in the second timepoint is greater or less than expected, according to the frequency of the same clone in the first timepoint. Adjusted p-values (q-value) were calculated using the false discovery rate (FDR) correction. Expanded clones were defined as having cell frequency greater than expected in the second timepoint (q-value<0.05), while contracted clones were defined as having cell frequency less than expected in the second timepoint (q-value>0.05). Clones without statistical significance for any test were classified as conserved clones.

Corresponding author(s): Michel Nussenzweig

Last updated by author(s): Nov 30, 2020
The data discussed in this publication have been deposited in NCBI's Gene Expression Omnibus (Edgar et al., 2002) and are accessible through GEO Series accession number GSE147182 (https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE147182)

Data

Policy information about availability of data
All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:
- Accession codes, unique identifiers, or web links for publicly available datasets
- A list of figures that have associated raw data
- A description of any restrictions on data availability

-GSE147182

Field-specific reporting

Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.

- Life sciences
- Behavioural & social sciences
- Ecological, evolutionary & environmental sciences

For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf

Life sciences study design

All studies must disclose on these points even when the disclosure is negative.

Sample size
The sample size of mice that were used per group/condition was not predetermined by statistical analysis but instead standard numbers that are accepted by the field. The number of mice used in each case allowed for rigorously testing of experimental hypothesis by appropriate statistical analysis to test the null hypothesis, minimize the probability of a false finding. Animal numbers also had to limited in accordance with the 3R's and ARRIVE guidelines, as to reduce the number of animals used to meet scientific objectives.

Data exclusions
Data only excluded for technical reasons, first bulk B cell RNA seq was excluded and repeated due to contaminants as observed by referee or if cells had died prior to adoptive transfer into host recipients.

Replication
Each experiment was repeated independently a minimum of two times and is stated in the Figure Legends. The bulk T cell RNAseq experiment was sequenced once, however was statistically powerful due the group size per condition. The 10xCiteSeq scRNAseq was repeated twice and a total of 6 mice were used to track clonal evolution longitudionally in the same individuals. All repeats were successful apart from one adoptive transfer experiment, where the experiment was ended prematurely due to a technical issue with the viability of the cells being delivered due to suspected overly harsh treatment during their isolation.

Randomization
Litter mate controls were used for in house strain and randomly assigned to groups. Otherwise out of house, C57BL/6 wild type mice were purchased from The Jackson and divided into sex matched and age matched groups.

Blinding
Mice were homogenous in sex and age prior to grouping. Investigators were not blinded in this study (as is accepted in the field) as blinding is not needed for a scientifically sound result. For mouse experiments it is required to provide a cage label for each experimental cage detailing the conditions each individual mouse has received, and each mouse needs to be identifiable with a ear marking, which prevents blinding in such experiments.

Reporting for specific materials, systems and methods

We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
## Antibodies

| Antibody/Dilution                                                                 | Dilution | Cat       | Lot            | Supplier   | Biocontent |
|---------------------------------------------------------------------------------|----------|-----------|----------------|------------|------------|
| anti-mouse Ki67, Alexa Fluor 488, Clone B56, Cat 558616, Lot 9123835, BD 1/100  |          |           |                |            |            |
| anti-mouse TCR DO11.10 FITC, Clone K11-26, Cat 118506, Lot B192696, Biolegend 1/200 |          |           |                |            |            |
| anti-mouse CD62L PE CY7, Clone MEL-14, Cat 104418, Lot B269976, Biolegend 1/200   |          |           |                |            |            |
| anti-mouse CD4 BUV395, Clone GK1.5, Cat 563790, Lot 9275330, BD 1/200            |          |           |                |            |            |
| anti-mouse C6c6 PE, Clone K112 91, Cat 561522, Lot B233984, BD 1/100              |          |           |                |            |            |
| anti-mouse Vβ 5.1, 5.2 T-Cell Receptor PE, Cat 553190, Lot 8345781, BD 1/200     |          |           |                |            |            |
| Biotin Rat anti-mouse CD185 (CXCR5), Cat 145510, Lot B21465, BD 1/100           |          |           |                |            |            |
| anti-mouse KI-67 FITC, Clone B56, Cat 558616, Lot 9123835, Biolegend 1/100       |          |           |                |            |            |
| anti-mouse KI-67 PE, Clone 16A8, Cat 652403, Biolegend 1/100                     |          |           |                |            |            |
| anti-mouse CD4, Clone RM4-5, Cat 100516, Lot B277608, Biolegend 1/200            |          |           |                |            |            |
| anti-mouse CD69 Pacific Blue, Clone H1.2F3, Cat 104524, Lot B287574, Biolegend 1/200 |          |           |                |            |            |
| anti-mouse CD69-FITC, Clone H1.2F3, Cat 104506, Lot E031177, Biolegend 1/200     |          |           |                |            |            |
| anti-CD45.2 Mouse Monoclonal Antibody PE, Clone 104, Cat 109808, Lot B271929, Biolegend 1/200 |          |           |                |            |            |
| anti-mouse CD185 (CXCR5) BViolet 421™, Clone L138D7, Cat 145512, Lot B265666, Biolegend 1/100 |          |           |                |            |            |
| anti-mouse TCR Va2, Clone B20.1, Cat 127807, Lot B245807, Biolegend 1/200        |          |           |                |            |            |
| anti-CD45.1 Mouse Monoclonal Antibody 110738, Biolegend 1/200                    |          |           |                |            |            |
| anti-mouse/human CD44 Brilliant Violet 421™, Clone IM7, Cat 103040, Lot B273304, Biolegend 1/200 |          |           |                |            |            |
| anti CD44, Clone IM7, Cat 11-0441-82, ebioscience 1/200                          |          |           |                |            |            |
| anti-mouse CD43 PE Antibody, Clone 57, Cat 553271, Lot 7297616, Biolegend 1/200  |          |           |                |            |            |
| anti-mouse CD4 APC, Cat 100516, Lot B277608, Biolegend 1/200                     |          |           |                |            |            |
| anti-mouse TCR DO11.10, Clone KJ1-26, Cat 118508, Lot B192696, Biolegend 1/200   |          |           |                |            |            |
| anti-mouse CD18, Clone 90/CD38, Cat 553764, BD Bioscience 1/100                  |          |           |                |            |            |
| anti-mouse PD1 PE, Clone J43, Cat 551892, Lot 7086579, BD Bioscience 1/200       |          |           |                |            |            |
| anti-mouse CD4 PE, Clone GK1.5, Cat 100408, Lot B266388, Biolegend 1/200         |          |           |                |            |            |
| anti-mouse CD45.2, Clone 104, Cat 109808, Lot B271929, ebioscience 1/200          |          |           |                |            |            |
| anti-mouse TCR VB5.1, Clone MR9-4, Cat 139504, Biolegend 1/200                   |          |           |                |            |            |
| anti-CD44, Clone IM7, Cat 103027, Biolegend 1/200                               |          |           |                |            |            |
| anti-mouse PD1- BV711, Clone 29F.1A12, Cat 135231, Lot B298863, Biolegend 1/200  |          |           |                |            |            |
| anti-mouse GL7 PB, Clone GL7, Cat 144614, Lot B306510, Biolegend 1/200           |          |           |                |            |            |
| anti-mouse GL7 FITC, Clone GL7, Cat 144603, Biolegend 1/200                      |          |           |                |            |            |
| anti-mouse CD44 BV605, Clone IM7, Cat 563058, BD 1/200                           |          |           |                |            |            |
| anti-NK.1.1 Mouse Monoclonal Antibody PE, Clone PK136, Cat 557391, Lot 65616, Biolegend 1/200 |          |           |                |            |            |
| anti-mouse CD38 Pacific Blue, Clone T10, Cat 102719, Biolegend 1/100              |          |           |                |            |            |
| anti-mouse/human PE CD45R/B220 Antibody, Clone RA3-682, Cat 103208, Biolegend 1/200 |          |           |                |            |            |
| anti-mouse CD86 APC, Clone Gl-1, Cat 4332810, Biolegend 1/100                    |          |           |                |            |            |
| anti-mouse CD279 APC, Clone 29F.1A12, Cat 109112, Lot B248540, Biolegend 1/200   |          |           |                |            |            |
| anti-mouse Active Caspase, Clone C92-605, Cat 561011, Lot 4318875, BD 1/100      |          |           |                |            |            |
| B-Phycoerythrin, Cat AS-82001, Lot 164-119, Anaspec 50uL of 4mg/ml B-PE in 150uL of PBS |          |           |                |            |            |
| Anti-B-Phycoerythrin Rabbit, 100 ng/100 ng/100 ng, Rockland 100ug of 10ng/ml DAPI solution, Cat 564907, Lot 9294998 10ug/ml |          |           |                |            |            |
| anti-mouse CD45.1 PE/Cyanine7, Clone A20, Cat 110729, Biolegend 1/200             |          |           |                |            |            |
| antibody TotalSeq™-C0301 anti-mouse Hashtag 1 Antibody 155861, Biolegend 1/100   |          |           |                |            |            |
| antibody TotalSeq™-C0302 anti-mouse Hashtag 2 Antibody 155863, Biolegend 1/100   |          |           |                |            |            |
| antibody TotalSeq™-C0303 anti-mouse Hashtag 3 Antibody 155865, Biolegend 1/100   |          |           |                |            |            |
| antibody TotalSeq™-C0304 anti-mouse Hashtag 4 Antibody 155867, Biolegend 1/100   |          |           |                |            |            |
| antibody TotalSeq™-C0305 anti-mouse Hashtag 5 Antibody 155869, Biolegend 1/100   |          |           |                |            |            |

### Validation

All fluorescent antibodies validated on the manufacturers website.
Eukaryotic cell lines

Policy information about cell lines

Cell line source(s) | OTII (in house) 293-6E (ThermoFisher)
Authentication | none.
Mycoplasma contamination | negative
Commonly misidentified lines | None used

Animals and other organisms

Policy information about studies involving animals. ARRIVE guidelines recommended for reporting animal research

Laboratory animals | C57BL/6, Do11.10, OTII, Fucci, SelCreERT2 ROSAtdT, C7, F1 (C57BL/6 x Balbc). All mice used were between 6-10 weeks of age and groups were age and sex matched. Mice were housed at a temperature of 72 °F and humidity of 30–70% in a 12-h light/dark cycle with ad libitum access to food and water. Male and female mice aged 8–10 weeks at the start of the experiment were used throughout.
Wild animals | No wild animals were used in this study.
Field-collected samples | none
Ethics oversight | All procedures in mice were performed in accordance to protocols approved by the Rockefeller University IACUC. All animal experiments were performed according to the protocols approved by the Institutional Animal Care and Use Committee of NIAID, NIH.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation | Single cell suspensions were obtained from popiteal lymph nodes or spleens of experimental mice, T cells and B cells were isolated by negative selection using PE-Easy Sep selection. Otherwise untouched single cell suspensions were stained for analysis.
Instrument | BD FACSARIAII, BD FACSSYMPHONY
Software | FACSDIVA version 8.0.2, FlowJo version v10.4.2
Cell population abundance | purity was above 95%
Gating strategy | Responding Tfh T cells were isolated by gating of live single cells that were CD4 positive, CD62 low, CD44 high, PD1 high, CXCXR5 high, and tdT +.

Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.